Online now: Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target
Posts by Thomas Kislinger
Raising a novel antibody, we demonstrate that FAT2 expression is associated with patient outcome. Reformatting to a CAR-T demonstrated anti-tumor activity in pre-clinical models.
We develop a PDX-based N-glycoproteomics strategy to discover cancer-enriched cell surface targets and identify FAT2 as a novel, largely unexplored squamous cell marker that is essential for cellular growth and survival.
Checkout our new paper published in @cp-cellrepmed.bsky.social
www.cell.com/cell-reports...
Fantastic work by Meinusha Govindarajan and Salvador Mejia-Guerrero with lots of help from our many collaborators and colleagues. #glycotime
Interested in surface proteomics for drug discovery?? Come to our @hupo-org.bsky.social Workshop on Sunday, Nov 9 at HUPO in Toronto! Excited to host with Amanda Lorentzain and learn from @berndwollscheid.bsky.social, Susan Klaeger and Thomas Kislinger!
CNPN2025 will be held on November 8th to kick off HUPO2025!
We have the honor to introduce our keynote speaker and fantastic invited speaker 🥳
@kislingerthomas.bsky.social and @philipplange.bsky.social
For more info about the program: cnpn.ca/cnpn2025/
#precisionmedicine #biomarkerdiscovery
And in case you missed it, here is her second, equally impressive second preprint.
www.biorxiv.org/content/10.1...
Latest preprint from the lab. Great work as always by Meinusha. This is the last chapter for her PhD.
www.biorxiv.org/content/10.1...
Interestingly, the urinary proteome of Black patients harboured more features of aggressive cancers than those of grade- and PSA-matched White patients. These observations highlight the importance of controlling for ancestry-associated differences in biomarker development.
This cohort was stratified by ancestry – thought to be a risk-factor for aggressive disease. We found surprisingly large differences and dysregulation of immune pathways.
After nearly 15 years of urine proteomics of prostate cancer patients, this is our most comprehensive work to date. We generated spectral libraries from hundreds of samples to rapidly analyze 329 post-DRE urines.
Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity: Cell Reports www.cell.com/cell-reports...
‪checkout our latest paper in @natbiotech.nature.com . We developed a graph-based algorithm that comprehensively generates non-canonical peptides in linear time. www.nature.com/articles/s41...
Identification of non-canonical peptides with moPepGen - @uclahealth.org @uoftmedicine.bsky.social @kislingerthomas.bsky.social go.nature.com/3HYJyyz
New collaborative work from PhD student Aastha. Using proteomics for CSF-based biomarker discovery
pubmed.ncbi.nlm.nih.gov/40321620/
I am everywhere and nowhere 👻
Last paper for 2024. Nice work by PDF Matt Waas on proteomics of HNSCC tissues to identify novel biomarkers within the N0 population. Great collaboration with Laurie Ailles
and support from many colleagues Princess Margaret Cancer Centre
Definitely also expressed in skin.
It gets upregulated in squamous carcinomas and is required for growth and survival
There is expression in the cerebellum for sure.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
Actually most datasets correlate reasonable well for Fat2. Since I have worked on this protein for the last 8 years
Let us know your thoughts
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers www.biorxiv.org/content/10.1101/2024.12....
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers www.biorxiv.org/content/10.1101/2024.12....